Docetaxel PK ± medicinal cannabis CSV JSON

In Vivo Interaction Study

Docetaxel PK ± medicinal cannabis

No Effect (based on bioequivalence limits) was detected.

docetaxel

medicinal cannabis

  • CYP3A

Table 3

Results

Table 3.

Sample Compound measured Measurement Value Study sequence Additional information N replicates

Experimental Conditions

Parallel

Population

Females
Males
Patients

No marijuana use

12

M = 7, F = 5
Age 58 (27-66)
All with metastatic cancer "for which irinotecan or docetaxel was considered an adequate option, which was refractory to conventional treatment or for which there was no standard regimen."
Please refer to Table 1 in the text for further information

Pharmacokinetic (PK) Sampling Information

Immediately prior infusion, 30 min after start, just before end of infusion; at 10, 20, 30 min, 1, 1.5, 2, 4, 5, 6, 7.5, 23, 31.5, and 47 hr after EOI

Drug or Natural Product Administration

Object Administration — docetaxel

Intravenous

Injection (250 mL NSS)

180 mg for first treatment, 135 mg or as per previous response for second treatment

Q3W

1-hr infusion, 3 weeks

Precipitant Administration — medicinal cannabis

Oral

Solution

18% THC, 0.8% CBD (200 mL, 1 g/L)

QPM

15 days starting day 10 of first treatment

Natural Product Characteristics

Office for Medicinal Cannabis, The Hague, The Netherlands

Herbal tea

Not specified